{
  "abstract": "High-dose methotrexate (HD-MTX)-based regimens, often combined with rituximab and alkylating agents, remain the induction backbone for primary central nervous system diffuse large B-cell lymphoma (PCNSL). We report outcomes of a less-intensive regimen of HD-MTX, rituximab, and temozolomide. In this single-center retrospective analysis, patients with newly diagnosed PCNSL received HD-MTX 3.5 g/m2 every 21 days for up to 8 doses, rituximab 500 mg/m2 every 21 days for 6 doses, and temozolomide 150 mg/m2 for 5 days every 42 days for up to 4 months. Forty patients (17 men, 23 women) were treated. Median age at diagnosis was 66 years (range, 28-89), and median Karnofsky performance status was 80 (range, 60-90). Thirty-two patients (80%) received at least 6 HD-MTX cycles; 3 (8%) discontinued HD-MTX due to nephrotoxicity. At the end of induction, the overall response rate was 95% and the complete response rate was 77%. With a median follow-up of 33.9 months, 2-year progression-free survival (PFS) and overall survival (OS) were 73% and 78%, respectively. In patients aged ≥70 years (n = 15), 2-year PFS and OS were both 72%. Two-year PFS and OS were 82% and 94%, respectively, after consolidation with high-dose chemotherapy and autologous stem cell transplantation (n = 17), and 89% and 86% with maintenance therapy (n = 9). This less-intensive regimen achieved favorable complete response rates, survival, and tolerability in patients with newly diagnosed PCNSL, including in patients aged ≥70 years, a population historically underserved by available treatments.",
  "abstract_shown": true,
  "affiliations": [
    "Northwestern University Feinberg School of Medicine, Chicago, IL.",
    "Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.",
    "Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago IL."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Michelle Rae Li"
    },
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Karan S Dixit",
      "orcid": "0000-0003-0403-6054"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e7r3hxsvvaakc.bib",
  "cited_by": 0,
  "doi": "10.1016/j.bneo.2026.100315",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13717732/?tool=EBI",
  "id": "e7r3hxsvvaakc",
  "issns": [
    "2950-3280"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13717732",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Lymphoid Neoplasia"
    ],
    [
      "openalex",
      "2728|CNS Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7213980633",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13717732/pdf/?tool=EBI",
  "pmcid": "PMC13717732",
  "pmid": "42959631",
  "published": "2026-09-22",
  "publisher": "The American Society of Hematology",
  "ris": "https://research.draconitic.com/paper/e7r3hxsvvaakc.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T00:20:39Z",
      "native_id": "PMC:PMC13717732",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13717732"
    },
    {
      "first_seen": "2026-11-01T00:20:52Z",
      "native_id": "MED:42959631",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42959631"
    },
    {
      "first_seen": "2026-11-02T12:22:00Z",
      "native_id": "PMC13717732",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.bneo.2026.100315"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|CNS Lymphoma Diagnosis and Treatment",
      "subfield": "neurology"
    }
  ],
  "title": "Dose-modified methotrexate, rituximab, and temozolomide induction achieves durable remissions in PCNSL",
  "title_text": "Dose-modified methotrexate, rituximab, and temozolomide induction achieves durable remissions in PCNSL",
  "type": "peer-reviewed",
  "updated_at": "2026-11-02T12:22:00Z",
  "url": "https://research.draconitic.com/paper/e7r3hxsvvaakc",
  "venue": "Blood neoplasia",
  "versions": []
}